Forbes November 22, 2025
Even as the acute phase of the COVID-19 pandemic fades, the world continues to wrestle with its aftermath — and nowhere is that more evident than in the enduring challenge of Long COVID. The condition, which affects an estimated 7% of U.S. adults, continues to frustrate patients and perplex researchers. Recent studies led by the National Institutes of Health (NIH) have provided a clearer picture yet of how Long COVID manifests and why treating it has proven so difficult. Meanwhile, major pharmaceutical firms are rebalancing their portfolios, cutting back on some mRNA programs while investing heavily in U.S.-based manufacturing to secure supply chains and pivot toward the next phase of innovation.
Long COVID has exposed both the limits of current...
Today's Sponsors
Today's Sponsor